Entity family

Browse treatments

Clinical therapies and care approaches used to manage a condition. Examples include immunotherapy, radiotherapy, rehabilitation.

4articles mentioning treatments

12treatment mentions

1distinct treatments extracted

0%of mentions human-reviewed

Active filtersEntity: DMTs ×

DMTs

This treatment is selected. Its supporting articles are shown below.

Articles mentioning DMTs

4 articles · page 1 of 1

182 Estimating eligibility for anti-amyloid therapy: a Nottingham perspective

jnnp · abstract · 2025-11-26 · 5 matching annotations

88.2%

DMTs Lecanemab donanemab NICE AD FDA Nottingham University Hospitals NHS Trust Alzheimer’s disease MCI Mild Cognitive Impairment

…our neurology-led tertiary referral clinics may be eligible for DMTs.priya.sharma15@nhs.net…

Single-centre, prospective cohort to predict optimal individualised treatment response in multiple sclerosis (POINT-MS): a cohort profile

bmjopen · abstract · 2025-09-25 · 3 matching annotations

89.6%

DMTs DMTs Multiple sclerosis MS National Hospital of Neurology and Neurosurgery University College London Hospital NHS Trust

…ncluding the high costs of disease-modifying treatments (DMTs). DMTs have substantially reduced the risk of relapse and moderately r…

5PSQ-083 Ofatumumab exposure until early pregnancy in a woman with relapsing-remitting multiple sclerosis: a case report

ejhpharm · abstract · 2026-03-18 · 2 matching annotations

80.8%

DMTs ofatumumab alemtuzumab interferon beta-1a natalizumab RRMS multiple sclerosis

…affects women of childbearing age. Disease-modifying therapies (DMTs) have improved prognosis but pose challenges when pregnancy is …

Comorbidities, safety and persistence in phase III clinical trials in multiple sclerosis

jnnp · abstract · 2025-10-15 · 2 matching annotations

78.3%

DMTs disease-modifying therapies multiple sclerosis cancer MS MS-DMTs

…mportant role of comorbidities in the safety and persistence of DMTs.…